Hermetica Superfood Encyclopedia
The Short Answer
Amarogentin is a bitter secoiridoid glycoside found primarily in Gentiana lutea (yellow gentian) root, notable for its exceptionally high bitterness index. It exerts metabolic and hepatoprotective effects largely by modulating GLUT4 glucose transporter expression in skeletal muscle and suppressing gluconeogenic enzymes such as PEPCK in the liver.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordamarogentin benefits
Synergy Pairings3
Amarogentin (Secoiridoid glycoside) — botanical close-up
Health Benefits
Origin & History
Natural habitat
Amarogentin is a secoiridoid glycoside isolated from medicinal plants including Gentiana lutea, Swertia chirata, and Gentiana rigescens. This naturally occurring bitter terpenoid is obtained from these plant sources through standard phytochemical isolation techniques.
“Amarogentin is derived from plants traditionally used in medicine, particularly Gentiana lutea and Swertia chirata. While specific historical uses of the isolated compound are not documented, the source plants have been employed as bitter tonics for liver, metabolic, and digestive disorders.”Traditional Medicine
Scientific Research
Current evidence for amarogentin is limited to preclinical animal and in vitro studies, with no human clinical trials identified. Key animal studies include diabetes models in rats (PMID: 27485449), liver fibrosis models in mice (PMID: 29112900), and thrombus formation models in mice (PMID: 24868545, 40849776).
Preparation & Dosage
Traditional preparation
No human dosage data available. Animal studies used: 100 mg/kg orally for liver fibrosis in mice, 9-18 mg/kg orally for antithrombotic effects in mice, and 15-60 μM in vitro for platelet studies. All studies used purified compound rather than standardized extracts. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Amarogentin is a pure bioactive secoiridoid glycoside compound (C29H30O13, molecular weight 584.53 g/mol), not a whole food ingredient, and therefore has no meaningful macronutrient, micronutrient, vitamin, mineral, or fiber profile. It is a secondary metabolite found primarily in Swertia chirata (Indian gentian) and related Gentianaceae species, where it occurs at concentrations of approximately 0.05–3.5% dry weight depending on plant part and species. As an isolated compound, it is studied in pure or near-pure form (≥98% purity in research contexts). Key bioactive characteristics: it is one of the most bitter naturally occurring substances known (detectable at ~58 parts per billion). It consists of a glucose moiety linked to a secoiridoid aglycone (swertiamarin-related structure) esterified with three gallic acid units. Bioavailability is limited by its high molecular weight and glycosidic nature; intestinal and hepatic hydrolysis by β-glucosidases is required for partial aglycone release. Oral bioavailability in animal models is low to moderate, with significant first-pass metabolism. It is poorly water-soluble, which further constrains systemic absorption. No protein, fat, carbohydrate, or micronutrient content is applicable to this isolated compound. Typical experimental dosing in animal models ranges from 10–100 mg/kg body weight orally.
How It Works
Mechanism of Action
Amarogentin upregulates GLUT4 (glucose transporter type 4) expression in skeletal muscle tissue, enhancing insulin-stimulated glucose uptake and improving peripheral insulin sensitivity. It concurrently suppresses phosphoenolpyruvate carboxykinase (PEPCK), a rate-limiting enzyme in hepatic gluconeogenesis, thereby reducing fasting glucose output from the liver. In hepatoprotective contexts, amarogentin appears to attenuate TGF-β1-driven stellate cell activation and collagen deposition, contributing to its anti-fibrotic profile observed in CCl4-induced liver injury models.
Clinical Evidence
Current evidence for amarogentin is confined to in vitro and animal studies, with no completed human clinical trials published as of early 2025. Diabetic rat models (streptozotocin-induced) have demonstrated improvements in fasting blood glucose and insulin sensitivity alongside measurable increases in skeletal muscle GLUT4 protein expression. Hepatoprotective effects, including reduced markers of fibrosis and liver enzyme normalization, were observed at an oral dose of 100 mg/kg in CCl4-injured rodents. The absence of human pharmacokinetic data, dose-ranging trials, and randomized controlled studies means all findings must be considered highly preliminary and not yet translatable to clinical recommendations.
Safety & Interactions
No formal human safety trials for isolated amarogentin have been published, making a comprehensive adverse effect profile impossible to establish at this time. As a potent bitter compound, high doses may cause gastrointestinal irritation, nausea, or increased gastric acid secretion, consistent with the broader gentian extract class. Theoretical pharmacodynamic interactions exist with antidiabetic medications (e.g., metformin, sulfonylureas, insulin) given its glucose-lowering mechanisms, potentially increasing hypoglycemia risk if combined. Amarogentin should be avoided during pregnancy and lactation due to the complete absence of safety data in these populations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Secoiridoid glycoside from GentianaGentiana bitter principleSwertia bitter compoundChirayita secoiridoidGentian glycosideBitter terpenoid glycoside
Frequently Asked Questions
What plant does amarogentin come from?
Amarogentin is isolated primarily from the root of Gentiana lutea (yellow gentian), a plant used in traditional European and Ayurvedic medicine for centuries. It is one of the bitterest naturally occurring compounds known, with a bitterness threshold detectable at concentrations as low as 1 part in 58 million. Smaller amounts also occur in related Gentiana species such as Gentiana kurroo.
Can amarogentin lower blood sugar?
In streptozotocin-induced diabetic rat models, amarogentin supplementation increased skeletal muscle GLUT4 expression and reduced hepatic PEPCK activity, resulting in measurable reductions in fasting blood glucose. These dual mechanisms—boosting peripheral glucose uptake and suppressing liver glucose production—suggest meaningful anti-diabetic potential. However, no human trials have been conducted, so its efficacy and safe dose for blood sugar management in people remains unestablished.
What is the difference between amarogentin and gentiopicroside?
Both amarogentin and gentiopicroside are secoiridoid glycosides derived from Gentiana species, but they differ structurally and in potency. Gentiopicroside (also called gentiopicrin) is the predominant bitter compound in gentian root by concentration, while amarogentin is present in smaller quantities but is approximately 3 times more bitter by threshold. Pharmacologically, gentiopicroside has a broader research base for gastroprotective effects, whereas amarogentin's research focus leans more toward metabolic and hepatoprotective mechanisms.
What dose of amarogentin was used in liver protection studies?
The hepatoprotective effects of amarogentin observed in published animal research were demonstrated at an oral dose of approximately 100 mg/kg body weight in CCl4-induced liver injury rat models. At this dose, researchers noted reduced hepatic fibrosis markers, decreased stellate cell activation, and normalized liver enzymes compared to untreated injured controls. This dosage has not been translated into a human-equivalent dose through formal pharmacokinetic bridging studies.
Is amarogentin safe to take as a supplement?
No human safety data specific to isolated amarogentin supplements currently exists, making it impossible to define a confirmed safe upper intake level. Gentian root extracts containing amarogentin have a long history of use as digestive bitters, but concentrated amarogentin isolates carry unknown risks, particularly regarding GI irritation and potential hypoglycemic drug interactions. Individuals taking diabetes medications, anticoagulants, or those who are pregnant or breastfeeding should consult a healthcare provider before use.
Does amarogentin have anticoagulant or blood-thinning effects?
Preliminary research suggests amarogentin may inhibit platelet aggregation and thrombus formation through the PLCγ2-PKC signaling pathway, indicating potential anticoagulant activity. However, this evidence comes primarily from in vitro and animal studies, and human clinical data on anticoagulant effects remain limited. Individuals taking antiplatelet or anticoagulant medications should consult a healthcare provider before supplementing with amarogentin to assess interaction risk.
What is the current quality of clinical evidence for amarogentin's effectiveness in humans?
Most efficacy data for amarogentin comes from preliminary animal studies (rodent models of diabetes and liver fibrosis) rather than rigorous human clinical trials. While these preclinical results are promising for blood sugar control, liver protection, and anti-inflammatory effects, evidence strength is considered preliminary and requires confirmation in human populations. More controlled clinical studies are needed before making strong claims about amarogentin's effectiveness as a therapeutic supplement.
Who might benefit most from amarogentin supplementation based on current research?
Based on preliminary evidence, individuals with elevated blood sugar, insulin resistance, or metabolic syndrome may be candidates for amarogentin, as studies show potential GLUT4 upregulation and improved glucose metabolism. Those with liver disease or risk factors for hepatic fibrosis might also benefit from its proposed hepatoprotective effects, though human efficacy data remain limited. Individuals with platelet aggregation disorders or those at thrombotic risk warrant medical supervision, given preliminary evidence of antiplatelet activity.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w amarogentin curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
